Astrazeneca Plc announce an interim dividend of $0.93 per share (71.8 pence, 9.64 SEK) has been declared.
Other financial highlights include:
‒ Total Revenue $22,295m, up 4% despite a decline of $2,181m from COVID-19 medicines
‒ Excluding COVID-19 medicines, Total Revenue increased 16% and Product Sales increased 15%
‒ Total Revenue from Oncology medicines increased 22%, CVRM 20%, R&I 10%, and Rare Disease 12%
‒ Core Product Sales Gross Margin of 83%, up three percentage points, reflecting the decline in sales of lower margin COVID‑19 medicines, the cost of production in prior periods, and ongoing mix shift to more speciality medicines
‒ In Q2 2023, Core Other operating income and expense included the previously-announced gain resulting from an update to the contractual relationships for Beyfortus (nirsevimab), totalling $712m
‒ Reiterating guidance for FY 2023 Total Revenue and Core EPS
